Febrile Neutropenia

High-Dose Chemotherapy: Safer and Better?.- Bone Marow Protectors in Cancer Treatment.- Hematopoietic growth factors in febrile neutropenia - Indications and limitations.- Incorporation of Quality-of-Life Considerations into Decisions Model for the Use of Colony-Stimulating Factors in Chemotherapy Patients at Risk for Febrile Neutropenia.- Assessing Risk in Cancer Patients with Fever and Neutropenia.- Therapeutic Approach in the Ambulatory Setting, Feasability and Surveillance.- The Sequence of Infective Events in Prolonged Neutropenia.- The Empirical Therapeutic Cascade: When to Start and When to Stop?.- Treatment of Neutropenic Infection: Trends Towards Monotherapy?.- The Changing Spectrum of Bacterial Infections in Febrile Neutropenic Patients.- Susceptibility of Streptococci Isolated from Blood of Neutropenic Patients to 11 Antibiotics.- Emerging Antibiotic Resistance in bacterial Pathogens.- Cefepime Versus Ceftazidime as Empiric Therapy of Febrile Episodes in Neutropenic Patients.- Cefepime Versus Ceftazidime in the Empiric Treatment of Febrile Neutropenic Children with Malignancy.- Cefepime-Vancomycin Versus Ceftazidime-Vancomycin as Empiric Therapy in Febrile Neutropenic Patients.- Monotherapy with Meropenem Versus Combination Therapy with Ceftazidime Plus Amikacin as Empiric Therapy for Fever in Granulocytopenic Patients with Cancer.- Piperacillin plus Tazobactam Versus Ceftazidime plus Amikacin in Febrile Neutropenia: A Comparison in Terms of Cost and Efficacy.- Fungal Infection in Neutropenic Patients: Past Achivements and Future Problems.- The Pressure of Emerging Resistance in Fungal Diseases.- Liposomal Versus Conventional Amphotericin B for the Treatment of Fever of Unknown Origin in Neutropenic Patients: Results of two Randomized Trials in 204 Children and 134 Adults.- Pulmonary Infiltrate Etiology in Leukemic Patients with Fever.- Marrow Transplantation: Current Results and Effect of Immunoglobulin Prophylaxis.- The Role of Economic Evaluation in